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Measles is one of the most contagious viral diseases known and 
can cause severe disease and death. Measles is vaccine preventable 
with a safe, effective and inexpensive vaccine that has been 
avail able since 1963. The World Health Organization (WHO) 
currently recommends two doses of measles-containing vaccine 
(MCV) for all children. In Africa, routine measles vaccination for 
infants started in the 1980s through the Expanded Program on 
Immunization. Subsequently, accelerated measles control using 
both routine vaccination and mass campaigns started in the 1990s. 
Estimated measles deaths in Africa decreased by 85% from 337 000 
in 2000 to 50 000 in 2010,[1] and in 2011, the goal of regional measles 
elimination by 2020 was set.[2]
Namibia, which gained independence from South Africa (SA) 
in 1990, had an estimated population of 2.1 million in 2009[3] (an 
annual growth rate of 2.6% was used to project a 2009 population) 
and a population density of 2.1 persons per square kilometre, the 
second-lowest population density in the world. The country is 
divided administratively into 34 health districts in 13 regions, inclu-
ding those with the highest populations in the northern part of 
the country along the border with Angola, and in the central and 
southern parts of the country. More than 67% of Namibian residents 
are rural dwellers.[4]
Routine measles vaccination began in Namibia in 1983, and the 
childhood routine immunisation schedule has included one dose of 
measles vaccine given to infants aged 9 months. In 1996, Namibia 
implemented an accelerated measles control strategy that included 
periodic mass vaccination campaigns. Despite these efforts, a large 
measles outbreak occurred during 2009 - 2011, affecting all areas of 
the country and people of all ages. To better understand the evolution 
of this outbreak and provide guidance for future measles elimination 
efforts, a study was conducted to describe the measles vaccination 
coverage through routine immunisation and supplementary 
immunisation activities (SIAs), and the measles epidemiology of the 
2009 - 2011 outbreak.
Methods
Routine immunisation and SIAs
From 1996 to 2011, the first dose of measles-containing vaccine 
(MCV1) was administered at age 9 months. Additional doses of MCV 
were given to infants and children during periodic SIAs. In addition 
to the administrative MCV1 coverage data reported by the Ministry of 
Health and Social Services, we analysed coverage estimates for MCV1 
provided by WHO/United Nations Children’s Fund (UNICEF) for 
children aged 1 year.[5] We calculated SIA administrative coverage by 
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Background. The World Health Organization, African Region, set the goal of achieving measles elimination by 2020. Namibia was one of 
seven African countries to implement an accelerated measles control strategy beginning in 1996. Following implementation of this strategy, 
measles incidence decreased; however, between 2009 and 2011 a major outbreak occurred in Namibia.
Methods. Measles vaccination coverage data were analysed and a descriptive epidemiological analysis of the measles outbreak was 
conducted using measles case-based surveillance and laboratory data.
Results. During 1989 - 2008, MCV1 (the first routine dose of measles vaccine) coverage increased from 56% to 73% and five supplementary 
immunisation activities were implemented. During the outbreak (August 2009 - February 2011), 4 605 suspected measles cases were 
reported; of these, 3 256 were confirmed by laboratory testing or epidemiological linkage. Opuwo, a largely rural district in north-western 
Namibia with nomadic populations, had the highest confirmed measles incidence (16 427 cases per million). Infants aged ≤11 months had 
the highest cumulative age-specific incidence (9 252 cases per million) and comprised 22% of all confirmed cases; however, cases occurred 
across a wide age range, including adults aged ≥30 years. Among confirmed cases, 85% were unvaccinated or had unknown vaccination 
history. The predominantly detected measles virus genotype was B3, circulating in concurrent outbreaks in southern Africa, and B2, 
previously detected in Angola.
Conclusion. A large-scale measles outbreak with sustained transmission over 18 months occurred in Namibia, probably caused by importation. 
The wide age distribution of cases indicated measles-susceptible individuals accumulated over several decades prior to the start of the outbreak.
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dividing the number of children vaccinated 
during an SIA campaign by the number of 
children targeted for vaccination as reported 
by Namibia to WHO.
Measles surveillance
We analysed annual measles cases reported 
using data from the WHO/UNICEF Joint 
Reporting Form from 1987 to 2011 and from 
national measles case-based surveillance data 
reported to the WHO from 2009 to 2011. [5] 
Case-based surveillance with laboratory 
testing for all suspected measles cases was 
introduced by the WHO Africa Regional 
Office in 1999.[6,7]
For case-based measles surveillance, 
the clinical case definition for suspected 
measles cases was an illness characterised 
by maculopapular rash, fever and one or 
more of conjunctivitis, coryza, and cough, 
or any illness in a patient in which the 
clinician suspected measles.[8] Investigations 
of suspected cases included collection of 
demographic and clinical information (i.e. 
age, sex, address, vaccination history and 
date of rash onset) and collection of a serum 
or urine specimen for laboratory testing. 
Suspected measles cases were subsequently 
classified as laboratory-confirmed, epidemi-
ologically linked, clinically compati ble 
or discarded, using the standard WHO 
algorithm. A suspected measles case was 
classified as laboratory confirmed if the case-
patient had a positive measles-specific IgM 
antibody test and had not received measles 
vaccination during the 30 days before rash 
onset. An epidemiologically linked case 
was defined as one meeting the suspected 
measles case definition and having contact 
(i.e. lived in the same district or adjacent 
districts with plausibility of transmission) 
with a laboratory-confirmed measles case 
with rash onset during the preceding 30 days. 
Suspected measles cases were considered 
confirmed either by laboratory testing or 
epidemiological link. Any cases that were 
reported in Namibia with a date of rash onset 
between 2 August 2009 (epidemiological 
week (epi-week) 31, 2009) and 2 February 
2011 (epi-week 5, 2011) were considered 
part of this outbreak. Incidence rates were 
calculated by dividing the total number of 
confirmed cases reported from each district 
by the district population and multiplying 
by 1 000 000. Data were analysed using 
Excel (Microsoft Corporation, USA) and 
SAS version 9.3 (SAS Institute, USA).
Laboratory diagnostics
Testing for measles-specific IgM antibody 
(anti-measles IgM) was performed at Namibia 
Institute of Pathology or the National Institute 
for Communicable Diseases (NICD), SA, 
using a standard ELISA (Enzygnost for IgM, 
Dade Behring, Germany). To identify circu-
lating measles virus genotypes, molecular 
diagnostic testing was performed at NICD. 
RNA was extracted from available specimens 
(serum or throat swab) using the QIAamp 
viral RNA mini-kit (QIAGEN, Germany), 
and amplified by reverse transcriptase-poly-
merase chain reaction (RT-PCR) using 
primers MeV214 and MeV216, designed to 
target a 634-nucleotide region coding for 
the 3´ terminus of the nucleoprotein (N) 
gene (measles genotyping kit v2.0, Centers 
for Disease Control, USA). Amplicons were 
sequ enced using standard protocols (BigDye 
Terminator v3.1 cycle sequencing kit, Applied 
Biosystems, USA). Measles virus genotypes 
were determined by phylogenetic analyses 
relative to the WHO measles reference strains 
using MEGA version 5.[9] 
Results
Routine immunisation and SIAs
The WHO and UNICEF estimates of cover-
age with MCV1 ranged from 58 to 77% 
between 1991 and 2011 (Fig. 1).[5] Five SIAs 































































































































































































Fig. 2. Confirmed* measles cases by epidemiological week and district, Namibia, 2 August 2009 - 
2 February 2011 (N=3 256). (ORI = outbreak response immunisation. *Confirmed measles cases were 
defined by laboratory confirmation or epidemiological link. †Target age group: 6 - 59 months. ‡Target age 
group: 6 months and older. §Target age group: 6 months - 35 years.)
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Fig. 1. Reported measles cases, estimated coverage with MCV1 and measles SIAs, Namibia, 1987 - 2011. 
(n/a = data not available. *Measles cases reported annually to WHO by member states through the 
WHO/UNICEF JRF.[13] †WHO/UNICEF national MCV1 coverage estimates for children aged 1 year. 
‡SIAs conducted in: June 1997 nationwide with administrative coverage of 92%; June 2000 nationwide 
with administrative coverage of 90%; June 2003 nationwide with administrative coverage of 94%; 
August 2006 subnational with administrative coverage of 90%; June 2009 with administrative coverage 
of 104%. Administrative coverage was calculated by dividing the number of measles vaccine doses 
administered by the targeted number of children and multiplying by 100.)
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2009 outbreak, in 1997, 2000, 2003, 2006 and 
2009.[10,11] The SIA conducted in 2006 was 
subnational; the other four were nationwide. 
All SIAs targeted children aged 9 - 59 months, 
with the exception of the 1997 SIA, which 
targeted children aged 9  months - 14 years. 
Reported administra tive vaccination coverage 
achieved during these SIAs ranged from 90 to 
104%. The 2009 SIA was conducted in June, 
~2 months before the measles outbreak began 
in Namibia. During September - December 
2009, an outbreak response immunisation 
(ORI) SIA was conducted in the six districts 
most affected by the outbreak at that time 
(Eenhena, Engela, Okongo, Opuwo, Outapi 
and Rundu) (Fig. 2). The ORI SIA was selective 
and targeted children aged 6 - 59 months 
who had never been vaccinated. However, 
the outbreak continued and in February 2010 
additional ORI activities were conducted 
in Opuwo district, target ing everyone aged 
6 months or older irres pective of previous 
vaccination status. During February and 
March 2010, ORI campaigns were conducted 
in Outapi, Onandjokwe and Rundu districts, 
targeting children aged 6 - 59 months irres-
pective of previous vaccination status.
Measles epidemiology and  
outbreak response
During the outbreak (2 August 2009 - 2 Feb-
ruary 2011), 4 605 suspected measles cases 
were reported in Namibia. Of these, 462 
(10%) were laboratory confirmed, 2 794 
(61%) were epidemiologically linked, 70 
(2%) were clinically compatible but no 
speci men was available for testing, and 
1 279 (28%) were discarded. Of the 3 256 
confirmed cases, most occurred during 2009 
(1 846 cases, 56.7%); 1 396 (42.9%) occurred 
in 2010, and 14 (0.4%) occurred in 2011 
(Table 1). Thirty-two (94%) of 34 districts 
reported three or more confirmed cases. 
Only Karasburg district reported no cases 
during the outbreak. Twenty-seven measles-
related deaths were reported.
Information on age and sex was available 
for 3 233 (99%) and 3 256 (100%) of the 
confirmed cases, respectively. Cases were 
widely distributed across all ages: 1 215 
(38%) cases occurred in infants and children 
aged <5 years (including 696 (22%) aged 
≤11 months), 791 (24%) in children aged 
5 - 14 years and 1 227 (38%) in persons aged 
≥15 years (Table 1 and Fig. 3). Infants aged 
≤11 months had the highest cumulative 
incidence during the outbreak (9 252 cases 
per million), followed by children aged 1 - 4 
years (2 306 per million) and those aged 
5 - 14 years (1 468 per million) (Table 2). In 
urban areas, large proportions of confirmed 
cases were aged ≤11 months or ≥15 years 
(29% and 47%, respectively) relative to rural 
areas (19% and 39%, respectively) (Table 2). 
Vaccination status information was avail-
able for 3 059 (95%) of confirmed cases; 
1 025 (34%) were unvaccinated and 1 570 
(51%) had unknown vaccination history 
(Table 1). The proportion of cases that had 
received ≥1 dose of MCV was 15% overall 
and low among all age groups: 11% in 
infants, 33% in children aged 1 - 4 years, 
25% in children aged 5 - 14 years, and 3% 
in those aged ≥15 years. In Windhoek, 92% 
of confirmed cases were either unvaccinated 
or had unknown vaccination status, and 
in Opuwo 81% of confirmed cases were 
unvaccinated and 13% had unknown status.
Before 2009, reported measles outbreaks in 
Namibia occurred in 1987, 1992, 1996 - 1997 
and 2002 - 2003 (Fig. 1). From 2004 to 2008, 
fewer than 10 measles cases were reported 
annually. During the first half of 2009, 14 
confirmed measles cases were reported; 
however, beginning in August 2009 (epi-week 
31), clusters of cases were reported, primarily 
in the Engela district in northern Namibia 
near the border with Angola. Reported cases 
increased sharply in epi-week 36 and peaked 
with 252 cases in epi-week 43 (Fig. 2).
During the first 5 months of the outbreak 
(epi-weeks 31 - 52, 2009), reported measles 
incidence in three districts along the Angola 
border was >1 000 per million population 
Table 1. Characteristics of confirmed measles cases,* Namibia, 2 August 2009 -  
2 February 2011
Namibia, n (%) Windhoek, n (%)† Opuwo, n (%)‡
Cases, N 3 256 839 765
Age group
<9 months 495 (15.3) 167 (20.1) 91 (11.9)
9 - 11 months 201 (6.2) 56 (6.7) 45 (5.9)
1 - 4 years 519 (16.1) 73 (8.8) 185 (24.2)
5 - 9 years 486 (15.0) 79 (9.5) 110 (14.4)
10 - 14 years 305 (9.4) 35 (4.2) 84 (11.0)
≥15 years 1 227 (38.0) 422 (50.7) 249 (32.6)
Missing 23 7 1
Sex
Male 1 642 (50.4) 457 (54.5) 370 (48.4)
Female 1 614 (49.6) 382 (45.5) 395 (51.6)
Vaccination 
status
0 doses 1 025 (33.5) 50 (6.2) 618 (80.8)
1 dose 393 (12.8) 53 (6.6) 38 (5.0)
≥2 doses 71 (2.3) 10 (1.2) 9 (1.2)
Unknown 1 570 (51.3) 693 (86.0) 100 (13.1)
Missing 197 33
Year of onset
2009 1 846 (56.7) 728 (86.8) 559 (73.1)
2010 1 396 (42.9) 111 (13.2) 206 (26.9)




462 (14.2) 76 (9.1) 25 (3.3)
Epi-linked 2 794 (85.8) 763 (90.9) 740 (96.7)
Outcome
Alive 3 226 (99.1) 831 (99.1) 761 (99.5)
Dead 27 (0.8) 7 (0.8) 3 (0.4)
Unknown 3 (0.1) 1 (0.1) 1 (0.1)
*Confirmed measles cases were defined by laboratory confirmation or epidemiological link.
†Outbreak dates: 3 August 2009 - 29 October 2010.
‡Outbreak dates: 8 September 2009 - 8 February 2010.
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(Fig. 4). Of the three districts, Opuwo had 
the highest confirmed incidence at 12 390 
cases per million population. Opuwo has a 
high concentration of Ovahimba pastoralist 
communities, and information collected 
during field visits and discussions with 
clinicians at the Opuwo district hospital 
showed that most cases occurred among 
Ovahimba communities. Ovahimba are 
Bantu pastoralists who are nomadic herders 
of cattle and goats; although they maintain 
homesteads, they migrate freely throughout 
Kunene region on the border with Angola to 
find fresh vegetation to feed their livestock. 
Between August and December 2009, the 
incidence in the capital district of Windhoek 
was 2 500 cases per million, and a total of 22 
(65%) districts had a measles incidence of 
≥50 cases per million (Fig. 4).
During the first half of 2010 (epi-weeks 
1 - 26), four districts had measles incidence 
≥1 000 cases per million, including Opuwo 
(3 935 cases per million) (Fig. 4). Measles 
incidence increased in most districts during 
the second half of 2010 (epi-weeks 27 - 52), 
but decreased to zero cases in Opuwo. 
Between 1 January and 2 February 2011 
(end of the outbreak), only Rundu in the 
north-east of the country had an incidence 
of ≥50 cases per million population 
(Fig. 4). Opuwo had the highest cumulative 
incidence (16 427 cases per million) during 
the 2009 - 2011 outbreak, followed by 
Kongo (6 357 cases per million), Outjo 
(2 873 cases per million), Windhoek (2 873 
cases per million), Rundu (2 304 cases per 
million) and Swakopmund (2 285 cases per 
million) districts.
Laboratory diagnostics
Genotype data were available for a total of 64 
specimens from the Namibia outbreak. For 
August - December 2009, all four specimens 
from Namibia were measles virus genotype 
B2. During 2010, 46 (94%) of 49 specimens 
were genotype B2, and 3 were genotype B3 
(6%). In 2011, 1 (9%) of 11 specimens was 
B2, and 10 (91%) were B3. Genotype B2 
was previously detected in Angola and the 
Democratic Republic of Congo, and B3 was 
the predominant genotype circulating in the 
outbreaks in southern Africa that started in 
SA during 2009 - 2010.[10]
Discussion
Even with accelerated measles control 
efforts in Namibia beginning in 1997, 
MCV1 coverage estimates ranged from 59% 
to 77% between 1991 and 2011. However, 
with periodic SIAs, annual reported 
measles incidence decreased to less than 
one case per million in Namibia by 2008 
and transmission of endemic measles virus 
was probably interrupted.[12] However, 
during 2009 - 2010, Namibia was one of 
several countries in southern Africa that 
experienced measles outbreaks following 
prolonged interepidemic periods. The out-
break in Namibia began in several districts 
in northern Namibia near the border with 
Angola; three of these districts reported 
measles incidence ≥1 000 cases per million, 
including Opuwo with the highest incidence 
of the outbreak of 12 390 cases per million. 
The likely cause of the outbreak was separate 
importations in 2009 and 2010 of measles 
virus genotypes B2 and B3. Because of 
an accumulation of unvaccinated, measles-
susceptible indi viduals, these importations 
resulted in sustained measles virus trans-
mission across multiple districts. The wide 
age distribution of cases suggests that 
the accumulation of measles-susceptible 
individuals occurred over several decades 
before the outbreak.
Despite modest routine measles immuni-
sation coverage and periodic SIAs, the 
Namibia outbreak started 2 months after a 
nationwide measles SIA targeting children 
aged 9 - 59 months was conducted in June 
2009 with 104% administrative coverage 
reported. Of confirmed cases during the 
outbreak, 22% were aged 9 - 59 months. 
Although most cases had missing or 
unknown information for vaccination status, 
our analysis suggested that the outbreak 
was due primarily to failure to achieve and 
sustain high two-dose measles vaccination 
coverage through routine immunisation 
services and SIAs.
The porous border between Angola and 
Namibia and persistently low routine measles 
vaccination coverage in Angola (MCV1 
cover age ranged from 41% to 74% bet ween 
2000 and 2006, and from 77% to 88% bet-
ween 2007 and 2009[13]) probably contributed 
Table 2. Age-specific confirmed measles incidence, Namibia, 2 August 2009 -  
2 February 2011
Age group
  0 - 11 months 1 - 4 years 5 - 14 years ≥15 years
Namibia (N=3 256)
Confirmed cases, n 696 519 791 1 227
Population, n 75 228 225 032 538 852 1 294 076
Incidence, n* 9 252 2 306 1 468 948
Proportion of cases, % 22 16 24 38
Proportion of population, % 4 11 25 61
Windhoek† (N=839)
Confirmed cases, n 223 73 114 422
Population, n 10 823 25 613 78 343 177 278
Incidence, n* 20 604 2 850 1 455 2 380
Proportion of cases, % 27 9 14 51
Proportion of population, % 4 9 27 61
Opuwo‡ (N=765)
Confirmed cases, n 136 185 194 249
Population, n 1 734 4 978 11 590 28 269
Incidence, n* 78 431 37 164 16 739 8 808
Proportion of cases (%) 18 24 25 33
Proportion of population (%) 4 11 25 61
Urban§ (N=1 188)
Confirmed cases, n 341 129 159 547
Proportion of cases, % 29 11 14 47
Rural (N=530)
Confirmed cases, n 98 83 141 203
Proportion of cases, % 19 16 27 39
*Per million.
†Outbreak dates: 3 August 2009 - 29 October 2010.
‡Outbreak dates: 8 September 2009 - 8 February 2010.
§Urban/rural residence information was missing for 1 538 (47%) of confirmed cases.
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to sustained measles virus transmission 
among population groups on both sides of 
the border. It was evident from field visits and 
discussions with the clinicians at the district 
hospital that most cases in Opuwo occurred 
among Ovahimba communities. Although 
acceptance of vaccination is high among the 
Ovahimba, strategies for delivering vaccin-
ation through routine services and SIAs 
have not adequately reached the nomadic 
communities. In addition, major challenges 
in reaching many of the rural communities 
in Opuwo district include the inaccessible 
topography (mountainous areas, impassable 
roads, etc.). Many hard-to-reach areas are 
only accessible by air.
In addition to cross-border transmission, 
nosocomial measles virus transmission 
prob ably played a role in sustaining the 
2009 - 2011 outbreak. Only two of the 
five district hospitals (Opuwo and Outapi) 
visited during fieldwork had a separate 
isolation ward for measles cases. In the 
other outpatient units visited, there was no 
evidence of an isolation unit and measles 
cases were hospitalised in the same wards 
as other inpatients. In addition, measles 
cases among nurses were reported during 
the outbreak.
Several limitations of these findings 
should be considered. First, under-repor-
ting of measles is well documented, so sur-
veillance data analysis represents only a 
fraction of cases. Therefore, our findings 
are representative of reported cases and do 
not account for unreported outbreak cases. 
Second, reported administrative vaccina-
tion coverage can be biased by inaccurate 
estimates of population denominators and 
reporting of doses delivered, resulting in 
inaccuracies in interpreting coverage and 
surveillance data. Third, comparisons of 
annual measles case totals and incidences 
may be inaccurate if completeness of case 
reporting varies from year to year.
To achieve the goal of measles elimination 
by 2020, additional efforts are needed in 
Namibia to strengthen routine immunisa-
tion services and SIA implementation, to 
achieve ≥95% two-dose coverage and close 
immunity gaps among measles-susceptible 
populations. Routine immunisation services 
should include outreach to communities 
that have poor access to routine services. 
Targeting SIA campaigns to include older 
ages, similar to the ORI SIA conducted in 
Opuwo, could improve immunity across 
a wider age range. Introducing a routine 
sec ond dose of measles-containing vaccine 
(MCV2) to the childhood immunisation 
schedule at age 15 - 18 months should be 
considered.[14,15]
The shift of measles epidemiology towards 
older age groups in Africa has been well 
documented.[7] However, follow-up SIAs 
have not addressed susceptibility among 
older age groups. SIA target age groups have 
been limited primarily due to inadequate 
resources. In April 2012, the Measles & 
Rubella Initiative launched the 2012 - 2020 
Global Measles and Rubella Strategic Plan 
to support rubella with measles elimination 
efforts.[16] The WHO recommends that the 
introduction of rubella-containing vaccine 
should include implementation of a catch-up 
SIA targeted at children across a wide range 
of ages using combined measles and rubella 
vaccine.[17] In addition to contributing to 
rubella elimin ation, these SIAs would provide 
a unique opportunity to boost population 
immunity to measles and contribute to the 
momentum needed to achieve and sustain 
measles elimination. For example, when 
combined measles and rubella vaccine is 
introduced in Namibia, the initial nationwide 
catch-up SIA using combined measles and 
rubella vaccine should have a target age 
group that includes young adults, to close the 
Fig. 3. Confirmed* measles cases (N=3 233†) by age in years, Namibia, 2 August 2009 - 2 February 
2011: A = Namibia; B = Windhoek; and C = Opuwo. (*Confirmed measles cases were defined by 
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immunity gaps that were identified during 
this measles outbreak.
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Fig. 4. Annualised reported measles incidence* and measles virus genotype by district, Namibia, 
2  August 2009 - 2 February 2011. (*Annualised measles incidence was calculated by dividing the 
number of confirmed measles cases from national measles case-based surveillance data in each time 
period by total annual population estimates from national census projections. †Each genotype symbol 
represents 1 - 15 specimens with that genotype detected.)
